Summary
The recently reported FACS-based CD107 assay has been used in human HIV and CMV antigen models as well as in the ex vivo analysis of tumor cytolytic T cells in a melanoma model by a single group. The purpose of our study was to validate this assay and to use it in previously untested viral and tumor antigen models. Specifically, we investigated the use of the novel CD107 cytotoxicity assay in the detection of influenza and HER2/neu tumor-specific cytolytic CD8+ T cells. CD8+ T cells from HLA-A2+ healthy donors were stimulated with autologous dendritic cells pulsed with FluM or the HER2/neu peptides, E75 or GP2. These CD8+ T cells were then tested in cytotoxicity assays at varying effector:target (E:T) ratios against T2 targets. Cytotoxicity was measured by detection of CD107a and b on the surface of CD8+ T cells. An E:T of 1:5 was found to optimize the resulting percentage of CD8+CD107+ T cells. E75- and GP2-stimulated CD8+ T cells were then tested in cytotoxicity assays with MCF-7 (HER2/neu+HLA-A2+) and AU565 (HER2/neu+HLA-A2-) tumor cells. Cytotoxicity was measured by both the CD107 assay and the 51Cr release assay. Results of cytotoxicity were then correlated between these two assays. In representative experiments, the CD107 assay identified average specific increases for E75- and GP2-stimulated cells of 4.26 and 3.57%, respectively. These results correlated favorably with cytotoxicity as measured by the traditional 51Cr assay. These findings confirm preliminary reports of the CD107 assay and suggest its usefulness for monitoring cancer trials.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
CG Ioannides B Fisk D Fan WE Biddison JT Wharton CA O’Brian (1993) ArticleTitleCytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER2/neu proto-oncogene Cell Immunol 151 225–234 Occurrence Handle10.1006/cimm.1993.1233 Occurrence Handle7691418
I Yoshino PS Goedegebuure GE Peoples AS Parikh JM DiMaio HK Lyerly AF Gazdar TJ Eberlein (1994) ArticleTitleHER2/neu-derived peptide(s) are shared antigens among human non-small cell lung cancer and ovarian cancer Cancer Res 54 3387–3390
ML Disis JW Smith AE Murphy W Chen MA Cheever (1994) ArticleTitleIn vitro generation of human cytolic T-cells specific for peptide derived from the HER-2/neu protooncogene protein Cancer Res 54 1071–1076 Occurrence Handle1:CAS:528:DyaK2cXisVWqtb8%3D Occurrence Handle7508819
GE Peoples PS Goedegeburre R Smith DC Linehan I Yoshino TJ Eberlein (1995) ArticleTitleBreast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide Proc Natl Acad Sci USA 92 432–436 Occurrence Handle1:CAS:528:DyaK2MXjt12qsbo%3D Occurrence Handle7831305
B Fisk TL Blevins JT Wharton CG Ioannides (1995) ArticleTitleIdentification of an immunodominant peptide of the HER-2/neu proto-oncogene recognized by ovarian tumor specific CTL lines J Exp Med 181 2709–2717 Occurrence Handle10.1084/jem.181.6.2109
TZ Zaks SA Rosenberg (1998) ArticleTitleImmunization with a peptide epitope (pp. 369–377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors Cancer Res 58 4902–4908 Occurrence Handle1:CAS:528:DyaK1cXnt1yis7c%3D Occurrence Handle9809997
KL Knutson K Schiffman MA Cheever ML Disis (2002) ArticleTitleImmunization of cancer patients with HER-2/neu, HLA-A2 peptide, pp. 369–377, results in short-lived peptide-specific immunity Clin Cancer Res 8 1014–1018 Occurrence Handle1:CAS:528:DC%2BD38XksVSqur0%3D
JL Murray ME Gillogly D Przepiorka H Brewer NK Ibrahim DJ Booser GN Hortobagyi AP Kudelka KH Grabstein MA Cheever CG Ioannides (2002) ArticleTitleToxicity, immunogenicity, and induction of E75-specific tumorlytic CTLs by HER-2 peptide E74 (369–377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer Clin Cancer Res 8 3407–3418 Occurrence Handle1:CAS:528:DC%2BD38XpsVCgt7o%3D Occurrence Handle12429628
P Brossart S Wirths G Stuhler VL Reichardt L Kanz W Brugger (2000) ArticleTitleInduction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells Blood 96 3102–3108 Occurrence Handle1:CAS:528:DC%2BD3cXnslGnt7w%3D Occurrence Handle11049990
K Kono A Takahashi H Sugai H Fujii AR Choudhury R Kiessling Y Matsumoto (2002) ArticleTitleDendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer Clin Cancer Res 8 3394–3400 Occurrence Handle1:CAS:528:DC%2BD38XpsVCgt7w%3D Occurrence Handle12429626
ML Disis KH Grabstein PR Sleath MA Cheever (1999) ArticleTitleGeneration of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine Clin Cancer Res 5 1289–1297 Occurrence Handle1:CAS:528:DyaK1MXkt1Oqur0%3D Occurrence Handle10389911
ML Disis TA Gooley K Rinn D Davis M Piepkorn MA Cheever KL Knutson K Schiffman (2002) ArticleTitleGeneration of T-cell immunity to the HER-2/neu peptide-based vaccines J Clin Oncol 20 2624–2632 Occurrence Handle10.1200/JCO.2002.06.171 Occurrence Handle1:CAS:528:DC%2BD38XkvF2mtr8%3D Occurrence Handle12039923
EC Dees KP McKinnon JJ Kuhns KA Chwastiak S Sparks M Myers EJ Collins JA Frelinger H Deventer ParticleVan F Collichio LA Carey ME Brecher M Graham HS Earp JS Serody (2004) ArticleTitleDendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer Cancer Immunol Immunother 53 777–785 Occurrence Handle10.1007/s00262-004-0520-1 Occurrence Handle15185007
MM Woll CM Fisher GB Ryan JM Gurney CE Storrer CG Ioannides CD Shriver JW Moul DG McLeod S Ponniah GE Peoples (2004) ArticleTitleDirect measurement of peptide specific CD8+ T cells using HLA-A2: Ig dimer for monitoring the in vivo immune response to a Her2/neu vaccine in breast and prostate cancer patients J Clin Imm 24 449–461 Occurrence Handle10.1023/B:JOCI.0000029117.10791.98 Occurrence Handle1:CAS:528:DC%2BD2cXkt1Oms7c%3D
JD Altman PA Moss PJ Goulder DH Barouch MG McHeyzer-Williams JI Bell AJ McMichael MM Davis (1996) ArticleTitlePhenotypic analysis of antigen-specific T lymphocytes Science 274 94–96 Occurrence Handle1:CAS:528:DyaK28XmtVyns7k%3D Occurrence Handle8810254
F Kern IP Surel C Brock B Freistedt H Radtke A Scheffold R Blasczyk P Reinke J Schneider-Mergener A Radbruch P Walden HD Volk (1998) ArticleTitleT-cell epitope mapping by flow cytometry Nat Med 4 975–978 Occurrence Handle10.1038/nm0898-975 Occurrence Handle1:CAS:528:DyaK1cXltVCisrs%3D Occurrence Handle9701254
ME Sheehy AB McDermott SN Furlan P Klenerman DF Nixon (2001) ArticleTitleA novel technique for fluorometric assessment of T lymphocyte antigen specific lysis J Immunol Methods 249 99–110 Occurrence Handle10.1016/S0022-1759(00)00329-X Occurrence Handle1:CAS:528:DC%2BD3MXhsFSju7c%3D Occurrence Handle11226468
JM Brenchley DC Douek DR Ambrozak M Chatterji MR Betts LS Davis RA Koup (2002) ArticleTitleExpansion of activated human naïve T-cells precedes effector function Clin Exp Immunol 130 432–440 Occurrence Handle10.1046/j.1365-2249.2002.02015.x Occurrence Handle1:STN:280:DC%2BD38npt1aksw%3D%3D Occurrence Handle12452833
L Liu A Chahroudi G Silvestri ME Wernett WJ Kaiser JT Safrit A Komoriya JD Altman BZ Packard MB Feinberg (2002) ArticleTitleVisualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates Nat Med 8 185–189 Occurrence Handle10.1038/nm0202-185 Occurrence Handle1:CAS:528:DC%2BD38Xht1equ7g%3D Occurrence Handle11821904
MR Betts JM Brenchley DA Price SC De Rosa DC Douek M Roederer RA Koup (2003) ArticleTitleSensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation J Immunol Methods 281 65–78 Occurrence Handle10.1016/S0022-1759(03)00265-5 Occurrence Handle1:CAS:528:DC%2BD3sXot1Olsrs%3D Occurrence Handle14580882
PJ Peters J Borst V Oorschot M Fukuda O Krahenbuhl J Tschopp JW Slot HJ Geuze (1991) ArticleTitleCytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes J Exp Med 173 1099–1109 Occurrence Handle10.1084/jem.173.5.1099 Occurrence Handle1:CAS:528:DyaK3MXhvVeks7s%3D Occurrence Handle2022921
V Rubio TB Stuge N Singh MR Betts JS Weber M Roderer PP Lee (2003) ArticleTitleEx vivo identification, isolation and analysis of tumor-cytolytic T cells Nat Med 9 1377–1382 Occurrence Handle10.1038/nm942 Occurrence Handle1:CAS:528:DC%2BD3sXosFOlurg%3D Occurrence Handle14528297
MR Betts DA Price JM Brenchley K Loré FJ Guenaga A Smed-Sorenson DR Ambrozak ST Migueles M Connors M Roederer DC Douek RA Koup (2004) ArticleTitleThe functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration J Immunol 172 6407–6417 Occurrence Handle1:CAS:528:DC%2BD2cXjs1Ois7k%3D Occurrence Handle15128832
M Barry RC Bleackley (2002) ArticleTitleCytotoxic T lymphocytes: all roads lead to death Nat Rev Immunol 2 401–409 Occurrence Handle1:CAS:528:DC%2BD38Xksl2murk%3D Occurrence Handle12093006
M Fukuda (2001) ArticleTitleLysosomal membrane glycoproteins: structure, biosynthesis and intracellular trafficking J Biol Chem 266 2127–2133
Author information
Authors and Affiliations
Corresponding author
Additional information
Funded by the Clinical Breast Care Project, a Congressionally funded program of the Henry M. Jackson Foundation for the Advancement of Military Medicine (Rockville, Maryland). Supported by the United States Army Medical Research and Materiel Command, and the Department of Clinical Investigations at the Walter Reed Army Medical Center. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of the Army or the Department of Defense.
Rights and permissions
About this article
Cite this article
Mittendorf, E.A., Storrer, C.E., Shriver, C.D. et al. Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides. Breast Cancer Res Treat 92, 85–93 (2005). https://doi.org/10.1007/s10549-005-0988-1
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10549-005-0988-1